Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Plos One|June 13, 2014
Real-time dopamine measurement in awake monkeysErik W Schluter, Andrew R Mitz, Joseph F Cheer, et al.
Neuroscience and Biobehavioral Reviews|April 25, 2017
The endocannabinoid system as a target for novel anxiolytic drugsSachin Patel, Mathew N Hill, Joseph F Cheer, et al.
Basal Ganglia|November 20, 2012
Cannabinoids and value-based decision making: implications for neurodegenerative disordersAngela M Lee, Erik B Oleson, Leontien Diergaarde, et al.
Cell Reports|September 15, 2015
Cocaine-Induced Endocannabinoid Mobilization in the Ventral Tegmental AreaHuikun Wang, Tyler Treadway, Daniel P Covey, et al.
Neuropharmacology|April 29, 2017
Endocannabinoid modulation of dopamine neurotransmissionDan P Covey, Yolanda Mateo, David Sulzer, et al.
Pharmacology Research & Perspectives|October 4, 2017
Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's diseaseDaniel S Whittaker, Huei-Bin Wang, Dawn H Loh, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 7, 2019
Enhanced striatopallidal gamma-aminobutyric acid (GABA)<sub>A</sub> receptor transmission in mouse models of huntington's diseaseTamara Perez-Rosello, Simon Gelman, Geoffrey Tombaugh, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 6, 2016
Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's DiseaseDan P Covey, Hannah M Dantrassy, Natalie E Zlebnik, et al.
Pageof 11